A case of accidental into-the-lens dexamethasone implant: watching or removing?

Maria Ludovica Ruggeri,Alberto Quarta,Rossella D’Aloisio,Lisa Toto,Rodolfo Mastropasqua

DOI: https://doi.org/10.1186/s12886-024-03538-y

IF: 2.086

2024-07-13

BMC Ophthalmology

Abstract:To report a case of cataract surgery in unintentional Ozurdex (Allergan, Inc., Irvine, California, USA) injection into the lens.

ophthalmology

What problem does this paper attempt to address?

Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens

Abdulrahman Albuainain,Mohanna Al Jindan,Bedoor Al Bloushi

DOI: https://doi.org/10.4103/1319-4534.305044

2020-01-01

Saudi Journal of Ophthalmology

Abstract:To report the therapeutic efficacy and results of an accidentally injected intralenticular sustained-release dexamethasone implant (Ozurdex) in a patient with macular edema secondary to diabetic macular edema. Dexamethasone intravitreal implant is an approved formulation in the management of macular edema. The most common adversarial effects are an elevation of intraocular pressure (IOP) and cataract, but the unintentional injection of the dexamethasone implant into the lens is a particularly rare event.We report a case of a 72-year-old man treated for resistant Diabetic macular edema (DME) with dexamethasone intravitreal implant (Ozurdex, Allergan, Inc., Irvine, CA, USA) in which the technique was complicated by accidental implantation into the lens body and review the management. The patient underwent phacoemulsification of the lens, removal of the Ozurdex, intravitreal Avastin injection, and implant of a one-piece lens in the posterior capsule.
Case Report: Dislocation Into Vitreous Cavity and Removal of a Posterior Chamber Phakic Intraocular Lens

Jingliang He,Li Zhang,Fang Zheng,Xiaoyun Fang

DOI: https://doi.org/10.3389/fmed.2021.792253

IF: 3.9

2022-01-01

Frontiers in Medicine

Abstract:Purpose: To report a rare case of delayed dislocation of a novel posterior chamber phakic intraocular lens into the vitreous cavity, which was successfully treated by a reformed technique. Case PresentationA 29-year-old female received Ejinn phakic refractory lens (EPRL) implantation to correct her high myopia. Spontaneous dislocation into the vitreous cavity occurred 26-months post-operatively without traumatic history. Pars plana vitrectomy combined with cutting the EPRL into two equal pieces was performed to remove the dislocated EPRL. ConclusionDislocation into the vitreous cavity of EPRL can be successfully and easily removed by our reformed technique. Concerns about zonules-related complications pre-operatively, intraoperatively, and post-operatively must be raised in the practice of EPRL implantation.
Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex)

Tim Beltraminelli,Jelena Potic,Theodor Stappler,Thomas J. Wolfensberger,Lazaros Konstantinidis

DOI: https://doi.org/10.1055/a-2215-8576

2024-04-25

Klinische Monatsblätter für Augenheilkunde

Abstract:The Ozurdex implant was designed to obtain a slow release of dexamethasone over a period of several months for the treatment of macular edema in the context of diabetic retinopathy or retinal vein occlusion, or in the treatment of noninfectious uveitis [1] [2] [3]. The treatment is administered through an intravitreal injection (IVT), and in the vitreous, it releases dexamethasone gradually over time, reducing inflammation and fluid buildup in the macula, thereby improving vision. Complications related to Ozurdex treatment are mostly ascribed to the known side effects of corticosteroid administration to the eye, namely, increased intraocular pressure (IOP), glaucoma, and cataract formation [4]. However, the risks caused by an IVT should be carefully weighted when considering an Ozurdex implant. Indeed, albeit very rare, cases of endophthalmitis have been reported [5]. Here, we present a case of another very rare complication, the inadvertent implantation of the Ozurdex implant into a crystalline lens. Received: 28 October 2023 Accepted: 15 November 2023 Article published online: 23 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

ophthalmology
Ozurdex insert dislocated to the anterior chamber after postration in a patient who underwent secondary implant surgery with Canabrava technique: A case report

Carla Sánchez Remacha,Cristina Calvo Simón,Luca Bueno Borghi,Miguel Castillo Fernández,Julia Aramburu Clavería,Marta Suñer Martínez,Pablo Cisneros Arias,Marta Orejudo De Rivas,Eva Josefina Nuñez Moscarda,Adrián Moñux Sánchez,Paula Casas Pascual,Francisco Javier Ascaso Puyuelo

DOI: https://doi.org/10.1111/aos.15967

2024-01-01

Acta Ophthalmologica

Abstract:Aims/Purpose: To present a case report of a 64‐year‐old man with dislocation of a dexamethasone anterior chamber (AC) implant, who underwent secondary implantation with the Canabrava technique. Methods: A male patient underwent surgery for a secondary implant in the left eye using the Canabrava technique. Post‐operatively, cystic macular oedema was observed on optical coherence tomography (OCT). After 15 days, with no anatomical improvement despite treatment with Nevanac eye drops, a dose of intravitreal injection with Ozurdex® was prescribed. A few days later, the patient came to the emergency department and reported seeing a foreign body in the treated eye. On biomicroscopic examination, an Ozurdex® insert was found in the AC. When the patient was questioned again, he stated that he had been in the praying position the previous days. A new macular OCT was performed, showing resolution of the foveal oedema. Dilation of the LAA with phenylephrine was performed with cephalic manoeuvres in the supine decubitus position, achieving the repositioning of the dexamethasone implant in the vitreous chamber. Finally, an OCT of the anterior pole shows that the secondary implant is normally positioned without complications. Results: After initial treatment with Ozurdex® intravitreal implant, total resolution of the post‐operative cystic macular oedema is achieved, even with dislocation to the anterior chamber. After outpatient management of the dislocation of the implant, we were able to relocate it to the vitreous chamber without the need for surgical management of the patient. Conclusions: In the clinical case, it is demonstrated that the anti‐inflammatory effect of Ozurdex® remains active despite dislocation of the implant to the anterior chamber. Likewise, a good ambulatory technique in the supine position with directed cephalic manoeuvres may be sufficient to reposition the implant without the need for surgery.

ophthalmology
Iatrogenic Macular Hemorrhage after Dexamethasone Implant Injection

Anna Friesacher,Sascha Mathias Jung,Scott Tschuppert,Christophe Valmaggia,Margarita G. Todorova

DOI: https://doi.org/10.1055/a-2282-3278

2024-04-25

Klinische Monatsblätter für Augenheilkunde

Abstract:We present a case of iatrogenic macular hemorrhage associated with an internal limiting membrane (ILM) rupture following intravitreal injection of a dexamethasone implant (0.7 mg Ozurdex: 6 mm long, 0.46 mm diameter, 0.0012 g). Received: 26 December 2023 Accepted: 29 February 2024 Article published online: 23 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

ophthalmology
Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®)

Daniel H Lee,Clement K Chan

DOI: https://doi.org/10.1016/j.ajoc.2020.100725

2020-04-30

Abstract:Purpose: We describe a modified injection technique that adheres a sustained-release dexamethasone intravitreal implant (Ozurdex®) to the vitreous base. Observations: This modified technique was applied after removal of a prior dislocated Ozurdex® that migrated into the anterior chamber in one patient, and also on another patient bothered by perception of a large floater induced by a free-floating Ozurdex® in the vitreous cavity previously inserted with the conventional technique. The main feature of this new technique consisted of altering the conventional "bevel-up" orientation of the insertion needle tip towards the vitreous cavity to the modified "bevel-down" orientation of the needle tip directed towards the pars plana and vitreous base, for the purpose of adhering a portion of or the entire dexamethasone implant to the vitreous base. Neither patient developed postoperative complications with this technique. Conclusions and importance: This modified insertion technique allows adherence of Ozurdex® to the vitreous base and avoids adverse effects associated with a free-floating Ozurdex®, such as its migration into the anterior chamber, or visual disturbance associated with movement of the implant.
Non-Pharmacological Aspects of Intravitreal Dexamethasone Implant Injections: A Retrospective Study of 3430 Injections and Complications

Mehmet Omer Kiristioglu,Gamze Ucan Gunduz,Nigar Abdullayeva,Selim Doganay,Ozgur Yalcinbayir

DOI: https://doi.org/10.1097/IAE.0000000000004270

2024-09-17

Retina

Abstract:Purpose: This study aims to evaluate the non-pharmacological safety profile of intravitreal dexamethasone (DEX) implants in cases with different etiologies. Methods: This retrospective university-based study analyzed clinical reports of patients receiving 0.7 mg DEX implant injections between 2013 and 2023. The study recorded patient demographics, injection indications, and follow-up data. Complications caused by the injection procedure and adverse events other than pharmacological side effects within a 3-month period were included. Results: In this study, 3430 DEX implant injections were made into 1471 eyes of 1091 patients. Non-pharmacological complications developed in 611 injections (17.8%). Subconjunctival hemorrhage was noted as the leading non-pharmacological complication (n=576, 16.8%). Sight-threatening 35 non-pharmacological adverse events and complications (1.0%) were recorded. Cases of anterior chamber migration, vitreous hemorrhage, retinal detachment, endophthalmitis, hypotony, and implant misplacement were observed. Cases requiring intensive treatments and additional surgical interventions were encountered. Conclusion: The injection of the DEX implant may lead to non-pharmacological complications caused by the mechanical impact of the injection or improper positioning of the implant, potentially resulting in vision loss. Severe outcomes such as corneal decompensation, retinal detachment, and endophthalmitis can ensue, emphasizing the gravity of these complications. Careful selection of patients and adherence to proper injection techniques are essential in reducing these risks.
A clinical case of intravitreal implant dexamethasone (Ozurdex) using in treatment of macular edema associated with non-infectious uveitis

L.P. Danilova,,O.V. Kolenko,D.A. Storozhilova,A.E. Shulga,L.P. Emanova,,,,,,,

DOI: https://doi.org/10.25276/2312-4911-2022-6-60-66

2023-10-29

Modern technologies in ophtalmology

Abstract:Purpose. Demonstration of a clinical case of macular edema treatment associated with non-infectious uveitis by intravitreal injection of a dexamethasone implant (Ozurdex). Material and methods. A clinical case of uveitis associated with rheumatoid arthritis in a 34-year-old female patient is presented. She underwent sequential two intravitreal injections (IVI) of long-acting dexamethasone (Ozurdex implants), with an interval of 3 months. Results. 3 days after Ozurdex IVI Vis OD = 1.0, Vis OS = 0.8 (initially 0.2), intraocular pressure (IOP) OD = 18 mmHg, IOP OS = 19 mmHg. A single cell suspension remained in the vitreous body. The retinal thickness in the macula decreased to 314.5 μm (initial 725.2 μm), and macula volume decreased to 14.1 mm3(initially 18.5 mm3 ). 3 months after IVI of Ozurdex in the vitreous: opacification +2 points, the implant was not detected due to its rapid biodegradation. OCT of the macular area again revealed edema with cystic cavities. Ozurdex was reinjected intravitreally. 3 days after the operation, all signs of the inflammatory process were stopped, Vis OD = 1.0, Vis OS = 1.0, IOP OD = 18 mmHg, IOP OS = 18 mmHg. Conclusion. The Ozurdex implant made it possible to achieve complete regression of macular edema and resorption of cell suspension in the vitreous body. The best-corrected visual acuity (BCVA) indicators increased significantly – from 0.4 to 1.0. Keywords: non-infectious uveitis, macular edema, Ozurdex implant, retinal thickness, macular volume.
[Lens injury as a complication of intravitreal medication injection]

Christoph R Clemens,Florian Alten,Nicole Eter,Horst Helbig,David A Märker

DOI: https://doi.org/10.1007/s00347-024-01997-8

Abstract:Background: Intravitreal medication injections are an efficient and low-risk delivery technique for treating various retinal diseases. Rare serious complications include increased intraocular pressure, vitreous hemorrhage, retinal tears and detachment, intraocular inflammation and endophthalmitis. In the case series presented here, we report iatrogenic lens injuries caused by inadequate performance of intravitreal injections. Methods: A multicenter data collection of patients treated with intravitreal injections with visible iatrogenic lens defects from 2016 to 2023 was retrospectively performed. Results: Lens trauma after intravitreal injections was identified in six cases (69.3±6.5 years). While five cases were observed after anti-VEGF therapy, we identified lens injury after dexamethasone implantation in one patient. Conclusion: Iatrogenic lens injury during intravitreal injection is preventable with the correct injection technique. Knowledge of individual axis length and lens status also helps to avoid this complication.
Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice

Kornwipa Hemarat,Jacquelyn D Kemmer,Travis C Porco,Alexander M Eaton,Rahul N Khurana,Jay M Stewart

DOI: https://doi.org/10.3928/23258160-20180831-05

2018-09-01

Abstract:Background and objectives: To determine the rate of ocular hypertension (OHT) after dexamethasone intravitreal implant in routine clinical practice and identify patient characteristics associated with a risk for glaucoma surgery. Patients and methods: The charts of 260 eyes from 221 patients with diabetic macular edema, retinal vein occlusion, uveitis, and macular edema secondary to various causes treated with one or more dexamethasone implants were reviewed. Intraocular pressure (IOP), medications, and glaucoma interventions were collected before and after implantation. Results: The mean baseline IOP was 14.3 mm Hg ± 3.6 mm Hg, and after receiving dexamethasone implant(s), 26.2% and 7.7% of patients had IOP greater than 25 mm Hg and 35 mm Hg, respectively. There was evidence (P < .001) of an association between preexisting glaucoma or glaucoma suspect status (103 eyes) and need for glaucoma surgery, and 4.62% (12 eyes) required glaucoma surgery. Conclusions: Secondary OHT induced by the dexamethasone implant can usually be controlled by medications, but the incidence of OHT requiring glaucoma surgery was high (4.62%) in our study relative to rates previously reported in the literature. All patients, especially those with preexisting glaucoma, should be advised of the possible need for glaucoma surgery prior to undergoing treatment with the dexamethasone implant. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:680-685.].
Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements

Giovanni Alessio,Francesco Boscia,Aldo Caporossi,Giacomo Panozzo,Michele Reibaldi,Giovanni Staurenghi,Monica Varano,Francesco Bandello

DOI: https://doi.org/10.1177/1120672120939500

2020-07-08

European Journal of Ophthalmology

Abstract:Purpose: Intravitreal corticosteroid implants based on sustained-release dexamethasone provide effective retinal delivery of drug for around 6 months for the treatment of diabetic macular edema (DME). As current recommendations on the management of patients with DME undergoing cataract surgery are limited, this article aims to highlight issues and provide guidance on the use of dexamethasone intravitreal implants (DEX-DDS) in patients with DME undergoing cataract surgery, based on the consensus findings of a panel of Italian experts. Methods: The panel developed a survey regarding the use of DEX-DDS in patients with DME undergoing cataract surgery, following a comprehensive literature search. The results of the survey were discussed at an experts’ meeting in September 2018, with a structured approach to determining consensus. The routine management of patients with DME undergoing cataract surgery was also developed for use as a basis of discussion to highlight current issues. Results: Eight consensus statements are presented, along with key issues that highlight controversial/outstanding issues in the use of DEX-DDS in DME patients with cataracts. Conclusion: The consensus statements can help provide practical guidance for clinicians in daily practice on the rationale, patient diagnosis and selection, and optimal management of patients with DME undergoing cataract surgery.

ophthalmology
LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY

Amina Rezkallah,Thibaud Mathis,Amro Abukhashabah,Nicolas Voirin,Ariane Malclès,Émilie Agard,Théo Lereuil,Philippe Denis,Corinne Dot,Laurent Kodjikian

DOI: https://doi.org/10.1097/IAE.0000000000003080

2021-07-01

Retina

Abstract:Purpose: To analyze the incidence, risk factors, and time to onset of ocular hypertension (OHT) after intravitreal injections (IVI) of dexamethasone implant and to evaluate the long-term cumulative probability of intraocular pressure elevation. Methods: Eyes of patients having received at least one dexamethasone implant IVI between October 2010 and February 2015 were included in the present study. Ocular hypertension was defined as intraocular pressure > 25 mmHg and/or an increase of 10 mmHg over the follow-up period compared with baseline intraocular pressure. Results: Four hundred ninety-four eyes were studied in 410 patients. For a total of 1,371 IVI, the incidence of OHT was 32.6% in the study eyes with a mean follow-up period of 30 months (3-62.5) and a median follow-up of 29 months. Pressure-lowering treatment was introduced for 36.9% of eyes. Topical treatment alone was sufficient to manage OHT in 97%. Young age, male sex, uveitis and retinal vein occlusion, and glaucoma treated with a double- or triple-combination topical pressure-lowering medication were found to be risk factors for OHT. The incidence of OHT did not change with an increase in the number of IVI, and there was no cumulative effect, defining by an increase of the incidence of OHT in patients after repeated IVI (P = 0.248). Conclusion: This study confirmed that OHT is of moderate incidence, transient, controlled by topical treatment and provides data on the long-term cumulative probability of intraocular pressure elevation in a large cohort of eyes treated with dexamethasone implant IVI. Repeat injections of dexamethasone implant neither increase nor decrease the risk of OHT.
Case report: Ultrasound biomicroscopy as a guide for the selection of injection sites for dexamethasone intravitreal implant (Ozurdex) for peripheral granulomatous ocular toxocariasis in children

Xin Zhang,Xinzhu Hou,Yan Zhang,Jingjie Liu,Zhiyong Zhang

DOI: https://doi.org/10.3389/fmed.2023.1176585

IF: 3.9

2023-05-16

Frontiers in Medicine

Abstract:Purpose This article aims to report a case of successful treatment of peripheral granulomatous ocular toxocariasis (OT) in an 8-year-old patient using intravitreal injection of dexamethasone (DEX) implant (Ozurdex) under ultrasound biomicroscopy (UBM) guidance. Case presentation A previously healthy 8-year-old boy with a history of long-term close contact with dogs complained of blurring of vision in the right eye for a year. Ophthalmic examination of his right eye showed chronic uveitis. Notably, UBM examination identified granulomas and peripheral vitreous strand in the ciliary body from 3 to 8 o'clock positions. Enzyme-linked immunosorbent assay (ELISA) results of the intraocular fluid (IF) and serum showed increased anti-Toxocara immunoglobulin G (IgG) levels, leading to a diagnosis of peripheral granulomatous OT in the right eye. Intraocular surgery was not indicated in this case. The treatment goal was to alleviate uveitis, improve visual acuity, and prevent complications. He was treated with an intravitreal injection of DEX implant, administered as a single dose every three months, total two doses, combined with albendazole, an oral anthelmintic. Under preoperative UBM guidance, two injections were performed at the 12 and 10 o'clock positions in the pars plana where there were no granulomas and peripheral vitreous strand, successfully preventing complications associated with intravitreal injection. After two injections, the patient's right eye vision improved significantly, with the best-corrected visual acuity (BCVA) increasing from 20/400 to 20/50. Vitreous opacity and retinal edema were reduced, preretinal proliferative membrane was stabilized, and no adverse events occurred. Conclusion UBM can accurately determine the location and extent of peripheral granulomas in OT patients, facilitating the avoidance of granulomas during intravitreal injection and preventing complications associated with intravitreal injection. Under the close follow-up and strict adherence to indications, preoperative UBM-guided intravitreal injections of DEX implant treatment for pediatric peripheral granulomatous OT are safe and effective, providing a new therapeutic option for pediatric peripheral granulomatous OT.

medicine, general & internal
Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis

Sergio Copete,Jose Gregorio García-García,Enrique Júdez

DOI: https://doi.org/10.1177/11206721241275729

2024-08-14

Abstract:Purpose: To describe our experience with the use of a sustained-release dexamethasone implant in three patients with recalcitrant macular edema that developed after necrotizing retinitis in the context of the previously treated virus. Case description: Two immunocompetent patients presented with unilateral acute retinal necrosis (ARN) due to Varicella-Zoster (VZV). The other, an immunocompromised patient, presented with unilateral cytomegalovirus (CMV) necrotizing retinitis. The diagnoses were confirmed by anterior chamber polymerase chain reaction (PCR) and all were treated with oral valganciclovir and intravitreal ganciclovir (2 mg/0.1 ml). Infection was controlled but two of them required pars plana vitrectomy. Between 2 and 4 months after the resolution of signs of infection, resistant macular edema (RME) developed, and an intravitreal dexamethasone device was implanted after anterior chamber PCR had been negative. Functional and anatomical improvement was achieved, with the resolution of the edema accompanied by improvement in visual acuity in all patients. There was no evidence of reactivation at two years. No cataract or ocular hypertension was observed. One patient required two additional dexamethasone implants. Conclusion: Dexamethasone intravitreal implant could be considered as an option for the treatment of macular edema developed after ARN. Care should be taken to avoid reactivation and patients need to be properly informed.
Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review

Livio Vitiello,Giulio Salerno,Alessia Coppola,Ilaria De Pascale,Giulia Abbinante,Vincenzo Gagliardi,Filippo Lixi,Alfonso Pellegrino,Giuseppe Giannaccare

DOI: https://doi.org/10.3390/life14060725

2024-06-03

Life

Abstract:Among working-age people, diabetic retinopathy and diabetic macular edema are currently considered the main causes of blindness. Nowadays, intravitreal injections are widely acknowledged as a significant milestone in ophthalmology, especially for the treatment of several retinal diseases, including diabetic macular edema. In particular, anti-vascular endothelial growth factor (VEGF) agents are typically the first line of treatment; however, monthly injections are required, at least, during the loading dosage. Notably, an intravitreal 0.7 mg dexamethasone (DEX) implant (Ozurdex®, AbbVie Inc., North Chicago, IL, USA) is considered a legitimate substitute treatment for diabetic eyes that have not responded to anti-VEGF treatment. In fact, clinical trials and real-life studies have demonstrated the effectiveness and safety of an intravitreal DEX implant in treating such conditions over a period of three to six months. For this reason, wisely selecting diabetic patients might be crucial to decreasing the load of injections in clinics and hospitals. The purpose of this review is to analyze the available scientific literature to highlight the benefits, efficacy, and clinical criteria for choosing whether to switch from intravitreal anti-VEGF therapy to an intravitreal DEX implant in diabetic macular edema.

biology
Central Retinal Artery Occlusion Following Intralesional Triamcinolone Injection for IgG4-related Orbital Disease

George Sanchez,Sudarshan Srivatsan,Hee Joon Kim,Robert C Kersten

DOI: https://doi.org/10.1097/IOP.0000000000002804

2024-09-27

Abstract:The risk of blindness associated with periocular and facial injections is well documented. Previous cases describing vision loss following a recent periocular or facial injection have emphasized the importance of facial "danger zones." To date, the literature suggests that nearly half of all cases of central retinal artery occlusion in the setting of a recent periocular or facial injection involve an injection in or around the nose. Here, the authors report the second known case of central retinal artery occlusion following a triamcinolone injection to the lacrimal gland. A 30-year-old female with a diagnosis of IgG4-related disease underwent lacrimal gland debulking with an intralesional steroid injection. She noted OD vision loss immediately after surgery, with posterior segment examination demonstrating retinal whitening with a cherry-red spot and intra-arterial yellow-white plaques. This case serves as a reminder to clinicians regarding the risk of iatrogenic embolism following triamcinolone injections around the face with special attention drawn to the lacrimal gland.
Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan

Motasem Al-Latayfeh,Mohammad Abdel Rahman,Raed Shatnawi

DOI: https://doi.org/10.2147/OPTH.S303670

2021-03-25

Clinical Ophthalmology

Abstract:Motasem Al-Latayfeh, 1, 2 Mohammad Abdel Rahman, 2 Raed Shatnawi 1, 2 1 Department of General and Special Surgery, School of Medicine, The Hashemite University, Zarqa, Jordan; 2 Department of Ophthalmology, Prince Hamza Hospital, Amman, Jordan Correspondence: Motasem Al-Latayfeh The Hashemite University, P.O. Box 150495, Zarqa, 13115, Jordan Tel +962797397711 Email motasem974@gmail.com Purpose: To analyze the real-life clinical outcome of a single dexamethasone implant (DEX) injection in the treatment of persistent diabetic macular edema (DME) after anti-vascular endothelial growth factor (anti-VEGF) agents in a sample of the Jordanian population. Methods: An observational case study design that involved a retrospective chart review analysis in a tertiary hospital in Amman, Jordan. Patients who showed persistent DME after receiving at least six doses of anti-VEGF agents for DME treatment were included. Results: The study population consisted of 72 participants (29 females, 43 males) having an average age of 66 years. All patients had best-corrected visual acuity (BCVA) less than 0.7 (6/9) and SD-OCT documented center-involved DME. The study results showed that the average baseline BCVA improved from 0.205± 0.1 before DEX injection to 0.358± 0.1 at 3 months post-injection (p< 0.0001). The central mean thickness (CMT) showed significant improvement also (539.347± 132.402 to 379.041± 99.430, p< 0.0001). There was a mean of 3 mmHg increase in intraocular pressure at 3 months post-injection (p< 0.0001), however, only 4% of patients required medical treatment. Other inflammatory biomarkers in OCT, such as intraretinal hyper-reflective dots (HRD), showed significant improvement also (23.67± 16 to 14.83± 13, p< 0.0001). No other significant safety concerns were noticed. Conclusion: A single DEX injection showed significant clinical and anatomical improvement in DME cases that are persistent after anti-VEGF treatment in our sample, with an excellent safety profile. In case of supply shortage of intravitreal injections, which occurs frequently at our center, a single DEX injection may be utilized as an effective DME therapy. Further research is mandated to identify clinical response in a larger sample and more frequent injections. Keywords: diabetic macular edema, dexamethasone, anti-VEGF, Ozurdex, Jordan
Subkonjuktivale Dexamethason-Implantation

Louise Massia Menkene,Clara Eileen Englisch,Warda Darwisch,Peter Szurman,Annekatrin Rickmann

DOI: https://doi.org/10.1055/a-2243-4507

2024-03-28

Klinische Monatsblätter für Augenheilkunde

Abstract:Eine 58-jährige Patientin wurde uns aufgrund eines rezidivierenden Makulaödems links bei chronisch-rezidivierender Uveitis anterior (HLA-B27+) zur Durchführung einer erstmaligen Injektion von Ozurdex (700 μg Dexamethason-Implantat, Allergan, Irland) überwiesen. Die Patientin hatte zuvor beim niedergelassen Augenarzt subkonjunktivale Dexamethason-Injektionen bekommen, die jedoch keine Besserung des Makulaödems brachten. Eine systemische Therapie wurde von der Patientin grundsätzlich abgelehnt. Received: 30 September 2023 Accepted: 28 December 2023 Article published online: 26 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

ophthalmology
Case report: Spontaneous lens absorption after the implantation of an implantable collamer lens

Xiaojing Liu,Qiulin Zeng,Ting Lu,Min Wang,Yong Sun,Jingfa Zhang

DOI: https://doi.org/10.3389/fmed.2023.1202691

IF: 3.9

2023-08-03

Frontiers in Medicine

Abstract:Background Spontaneous lens absorption is rare and usually occurs in eyes with certain syndromes, hyper-mature cataracts, and ocular trauma. The application of an implantable collamer lens (ICL) is widely performed in patients with high myopia for refractive correction. This study reports a case of spontaneous lens absorption after ICL implantation. Case summary A 23-year-old man was referred with complaints of poor vision in his left eye. The patient had undergone binocular ICL implantation for refractive correction of high myopia 1.5 years prior. Approximately 10 months later, he experienced a sudden loss of vision and pain in his left eye, which resolved spontaneously the next day without any treatment. Since then, the visual acuity in his left eye gradually decreased. At presentation, slit-lamp examination revealed an ICL in the posterior chamber of both eyes, with anterior capsular fibrotic proliferation and posterior capsular opacity, and the residual lens cortex sandwiched between the anterior fibrotic membrane and opacified posterior lens capsule in his left eye. The number of corneal endothelial cells in his left eye was 1,337, which was lower than before ICL implantation (2,902). The patient then underwent ICL extraction, anterior capsular capsulotomy, residual cortex aspiration, posterior capsular polishing, and intraocular lens implantation. Conclusions Spontaneous lens absorption may occur in patients with ICL implantation. Patients should undergo routine follow-ups after ICL implantation.

medicine, general & internal
Corneal decompensation due to spontaneous absorption of lens and anterior dislocation of lens capsule: A case report.

Shuangqing Wu,Xiaoyu Yu,Qi Dai,Yana Fu,Xiaolei Lin

DOI: https://doi.org/10.1097/MD.0000000000018417

IF: 1.6

2019-01-01

Medicine

Abstract:Rationale: Spontaneous absorption of lenses or cataracts is rare. However, lens capsule attachment to the endothelium combined with corneal decompensation can still occur. Patient concerns: An 81-year-old male presented with left eye pain and bulbar conjunctival injection for 6 months. Diffuse corneal edema and inferior bullous lesions were observed by slit-lamp microscopy. Following examination with swept-source optical coherence tomography, we could clearly identify a membrane structure adherent to the corneal endothelium, as well as a lens not in situ. In vivo confocal microscopy found decreased corneal endothelial density of 745 +/- 46 cells per mm(2) in the left eye. Diagnosis: Lens dislocation and spontaneous absorption, combined with corneal decompensation were diagnosed. Interventions: Surgical removal of the membrane structure combined with anterior vitrectomy was performed. Outcomes: The patient's symptoms were partly relieved. However, the corneal endothelial decompensation could not be entirely reversed. In vivo confocal microscopy verified that corneal endothelium was in situ and the density was not significantly changed in the left eye. Lessons: This case study reports a rare dislocation and spontaneous absorption of lens without any trauma or subsequent surgery. Moreover, it demonstrates corneal endothelial decompensation due to the lens capsule adhering to the corneal endothelium. Timely intervention is required to remove the dislocated lens and prevent complications.

A case of accidental into-the-lens dexamethasone implant: watching or removing?

Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens

Case Report: Dislocation Into Vitreous Cavity and Removal of a Posterior Chamber Phakic Intraocular Lens

Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex)

Ozurdex insert dislocated to the anterior chamber after postration in a patient who underwent secondary implant surgery with Canabrava technique: A case report

Iatrogenic Macular Hemorrhage after Dexamethasone Implant Injection

Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®)

Non-Pharmacological Aspects of Intravitreal Dexamethasone Implant Injections: A Retrospective Study of 3430 Injections and Complications

A clinical case of intravitreal implant dexamethasone (Ozurdex) using in treatment of macular edema associated with non-infectious uveitis

[Lens injury as a complication of intravitreal medication injection]

Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice

Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements

LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY

Case report: Ultrasound biomicroscopy as a guide for the selection of injection sites for dexamethasone intravitreal implant (Ozurdex) for peripheral granulomatous ocular toxocariasis in children

Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis

Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review

Central Retinal Artery Occlusion Following Intralesional Triamcinolone Injection for IgG4-related Orbital Disease

Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan

Subkonjuktivale Dexamethason-Implantation

Case report: Spontaneous lens absorption after the implantation of an implantable collamer lens

Corneal decompensation due to spontaneous absorption of lens and anterior dislocation of lens capsule: A case report.